Allarity Therapeutics (NASDAQ:ALLR) stock is taking off on Tuesday after the clinical-stage biopharmaceutical company released data from a Phase 2 clinical trial of stenoparib.
That clinical trial saw the company testing the effectiveness of stenoparib in women with advanced ovarian cancer. The good news is that of the five women in the study, one achieved a complete response and the other four showed stable disease.
While this is still early data from the clinical trial, the results are looking promising for stenoparib as an advanced ovarian cancer treatment. That has the company hoping for even more good news once the study comes to a close.
What’s Next for ALLR Stock?
Allarity Therapeutics will be awaiting further data from this Phase 2 clinical trial. That includes interim data that will be released in the first quarter of 2024. The company is hopeful that it will meet its primary endpoint of objective response rate when the final results come in.
With today’s news comes heavy trading of ALLR stock as investors buy the shares. As of this writing, more than 37 million shares of ALLR stock have been traded. To put that in perspective, the company’s daily average trading volume is closer to 192,000 shares.
ALLR stock is up 42.3% as of Tuesday morning.
Investors looking for more of the latest stock market news today are in the right place!
InvestorPlace is home to all of the hottest stock market news that traders need to know about on Tuesday! A few examples include what’s going on with shares of Nokia (NYSE:NOK), Albemarle (NYSE:ALB) and SilverSun Technologies (NASDAQ:SSNT) stock today. All of that info is available at the following links!
More Stock Market News for Tuesday
- NOK Stock Alert: AT&T Sends Nokia Plunging to 3-Year Low
- Piper Sandler Is Souring on Albemarle (ALB) Stock
- Why Is SilverSun Technologies (SSNT) Stock Down 28% Today?
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
